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Abstract
Bortezomib (Velcade
TM) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma (MM).
Despite its demonstrated clinical success, some patients are deprived of treatment due to primary refractoriness or
development of resistance during therapy. To investigate the role of the duration of proteasome inhibition in the anti-tumor
response of bortezomib, we established clonal isolates of HT-29 adenocarcinoma cells adapted to continuous exposure of
bortezomib. These cells were ,30-fold resistant to bortezomib. Two novel and distinct mutations in the b5 subunit,
Cys63Phe, located distal to the binding site in a helix critical for drug binding, and Arg24Cys, found in the propeptide region
were found in all resistant clones. The latter mutation is a natural variant found to be elevated in frequency in patients with
MM. Proteasome activity and levels of both the constitutive and immunoproteasome were increased in resistant cells, which
correlated to an increase in subunit gene expression. These changes correlated with a more rapid recovery of proteasome
activity following brief exposure to bortezomib. Increased recovery rate was not due to increased proteasome turnover as
similar findings were seen in cells co-treated with cycloheximide. When we exposed resistant cells to the irreversible
proteasome inhibitor carfilzomib we noted a slower rate of recovery of proteasome activity as compared to bortezomib in
both parental and resistant cells. Importantly, carfilzomib maintained its cytotoxic potential in the bortezomib resistant cell
lines. Therefore, resistance to bortezomib, can be overcome with irreversible inhibitors, suggesting prolonged proteasome
inhibition induces a more potent anti-tumor response.
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Introduction
The proteasome is a multicatalytic proteolytic structure that is
responsible for the degradation of intracellular proteins [1]. Three
distinct catalytic activities comprise the proteasome: chymotrypsin-
like (CT-L), caspase-like (C-L), and trypsin-like (T-L). These
activities are encoded in the broadly expressed constitutive (c20S)
form of the proteasome by b5, b1, and b2, respectively. Another
form of the proteasome that is primarily expressed in cells of
hematopoietic origin and cells exposed to inflammatory cytokines,
known as the immunoproteasome (i20S), has the three catalytic
activities represented by LMP7, LMP2, and MECL1. In cells that
express both types of proteasomes, hybrid ensembles containing
both c20S and i20S catalytic subunits have been described [2].
Proteasome inhibition leads to the accumulation of unfolded or
oxidatively modified proteins in the intracellular environment,
which causes an overload in the endoplasmic reticulum (ER). The
ER stress response initially induces a pro-survival response by
activating the unfolded protein response (UPR) to promote
refolding or elimination of unfolded proteins [3]. Three signaling
modules of the unfolded protein response are activated: i)
Regulation of translation by PERK activation of ATF4, ii)
regulation of proteolysis by cleavage ATF6 and translocation to
the nucleus, and iii) transcriptional control by IRE1 splicing of
XBP1u mRNA. If pro-survival mechanisms are overwhelmed by
protein overload or are malfunctioning, apoptosis is induced [3].
In B-cell neoplasms, targeting the proteasome with small molecule
inhibitors has led to new therapeutic strategies. The first
proteasome inhibitor to gain FDA approval is the reversible
dipeptide boronate boretezomib (Velcade
TM), which is approved
for the treatment of multiple myeloma (MM) and mantle cell
lymphoma [4]. The clinical success of bortezomib has led to the
development of several other small molecule inhibitors encom-
passing multiple chemical classes [5,6].
Despite the overwhelming success of bortezomib in the
treatment of MM, a subset of bortezomib naı ¨ve patients fail to
respond to therapy and others develop resistance upon relapse
[7,8]. The study of resistance to bortezomib has involved gene
expression profiling in patient derived tumor cells [9] and the
generation of cell lines with acquired resistance to bortezomib
[10–15]. Increased expression of the ER stress response pathways
has been noted in both settings [9,16]. Whether these mechanisms
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defense against proteasome inhibitor pressure is unclear. In
addition, increased expression levels of the proteasome
[11,13,15,17,18] and mutations in the b5 subunit [12,13,17,19],
the primary target of bortezomib, have been described in cells
adapted to bortezomib in vitro. However, no mutations in b5 have
been detected in myeloma patients refractory to or relapsed from
bortezomib treatment [20].
We describe here the generation of bortezomib resistant cells in
HT-29 adenocarcinoma cells to investigate the role of proteasome
duration in cytotoxicity. We chose a solid tumor cell line to pursue
our studies since the dynamic window between complete
proteasome inhibition and cytotoxicity is larger than in hemato-
logic tumor cell lines [21]. The clonal isolates conditioned to
bortezomib displayed a stable resistance of 30–60 fold relative to
parental cells These cells were globally analyzed for expression and
genetic changes and specifically assessed for biochemical, expres-
sion, and genetic changes to proteasome active sites. We found
that these resistant cells had a novel mutation within the mature
b5 and a mutation in the propeptide region of the b5 subunit
which is a natural variant found at a higher frequency in multiple
myeloma patients. The resistant cells also had an increased subunit
expression of multiple proteasome subunits that resulted in cells
that had higher basal proteasome activity. Further, these cells
recovered proteasome activity more rapidly following brief
exposure to bortezomib. Interestingly, we found that proteasome
inhibitors with an irreversible mechanism of action could
overcome bortezomib resistance in these cells, suggesting that
prolonged inhibition of the proteasome induces a more potent
cytotoxic response to tumor cells.
Materials and Methods
Cell culture
HT-29 cells (American Type Culture Collection, Manassas, VA)
were cultured in 37uC incubators with 5% CO2, using McCoy’s 5a
with L-glutamine and supplemented with 10% fetal bovine serum
(FBS), 2.2 g/l sodium bicarbonate, 100 units/ml penicillin,
100 units/ml streptomycin (Mediatech; Manassas, VA) and 1.5 g/
l D-glucose (Sigma Aldrich; Carlsbad, CA). Drug treatment media
used in assays was composed of McCoy’s 5a with L-glutamine
supplemented with 10% FBS, 100 units/ml penicillin and
100 units/ml streptomycin. Both parental and bortezomib-condi-
tioned HT-29 cells were maintained as adherent cells in corning
175 mm
2 flat bottom flasks. These adherent cells were passaged
using trypsin/EDTA (Mediatech) and plated at 4.0610
5 cells/cm
2.
Reagents
Cycloheximide was purchased from Enzo Life Sciences (Ann
Arbor, MI) and dissolved to a stock concentration of 25 mg/ml in
DMSO and further diluted to 1 mg/ml for cell culture
experiments. Carfilzomib was manufactured at Onyx Pharma-
ceuticals, Inc. Bortezomib (VelcadeH; Millennium Pharmaceuti-
cals) was purchased from a local pharmacy. Carfilzomib was
dissolved in dimethyl sulfoxide (DMSO; Sigma Aldrich; Carlsbad,
CA) to a stock concentration of 10 mM while bortezomib was
dissolved in saline (0.9%; Sigma Aldrich) to a stock concentration
of 2.6 mM. Both compounds were further diluted in DMSO to
their respective working concentrations with a final concentration
of DMSO at 0.25% in each experimental condition. Cbz-Leu-
Leu-Leu-Boronic acid was obtained from AG Scientific, Inc. (San
Diego, CA) and dissolved in DMSO to a final concentration of
10 mM. The reconstituted stock compounds were dispensed into
single-use aliquots and stored at 280uC until use.
Isolation of bortezomib-resistant single cell clones
HT-29 cells were cultured with continuous stepwise increases in
bortezomib concentration (20 nM to 200 nM) over 7 months.
Clonal isolates were derived by 2 separate limiting dilution
analyses in 96-well plates under constant bortezomib exposure of
100 nM or 200 nM for an additional 4 months.
Cell viability assay
Cell viability was measured after 72 hr of continuous drug
treatment using CellTiter-GloH (Promega Corp.; Madison, WI)
according to the manufacturer’s instructions. Clonal populations
stably growing under bortezomib pressure were harvested,
washed to remove free bortezomib to allow proteasome recovery,
then plated in 96-well plates (3610
4 cells/well) for 3–40 days
prior to the assay day; parental HT-29 cells (no prior exposure to
bortezomib) were assayed in parallel. Serial dilutions of
bortezomib or carfilzomib were added to replicate wells to
obtain dose responses. Cell viability experiments were performed
in triplicate for each cell line. Viability (average of duplicate
determinations at each dose) was then plotted against drug
concentration for each drug/cell line combination, and the best-
fit curve was determined using a four-parameter (sigmoidal)
model. Data analysis was performed using GraphPad Prism (v5;
San Diego, CA).
Western blot analysis
HT-29 parental and bortezomib-resistant cells were cultured as
described above. At different time points, cells were harvested and
cells were lysed in 0.2% Triton X-100 with protease inhibitor
cocktail (Roche; South San Francisco, CA). Lysates were
normalized by protein assay then resolved on NuPage gels
(Invitrogen; Carlsbad, CA), transferred to nitrocellulose, and
probed with antibodies to b1, b2, b5, LMP2, LMP7 and MECL1.
HRP-conjugated secondary antibodies were used to detect the
immunoreactive bands, followed by chemiluminescence detection
(Thermo Scientific; Rockford, IL).
20S proteasome activity assay
Cells were incubated for 1 hr with serial dilutions of
carfilzomib or bortezomib followed by washing with media and
allowed to recover their proteasomes for 1, 2, 4, 6, 8, 12 or 24 hr
or immediate washed with phosphate buffered saline (PBS) and
resuspended in 30 ml lysis buffer (20 mM Tris pH 8 and 5 mM
EDTA). Cells were kept frozen at 280uC until use. The day of
the assay, cells were thawed on ice, centrifuged at 3000 rpm for
20 min and the supernatants were combined with the specific
fluorogenic substrate in a 384-well plate. The chymotrypsin-like,
trypsin-like, and caspase-like activities of the cellular 20S
proteasomes were determined by measuring the appearance of
a fluorescent cleavage product generated from the fluorogenic
substrates Suc-LLVY-AMC, Bz-VGR-AMC, and Z-LLE-AMC
(Boston Biochem Inc., Cambridge, MA), respectively. The
samples were analyzed on a spectrofluorometer (Tecan Safire;
San Jose, CA), using an excitation of 380 nm and an emission of
460 nm.
Proteasome active site ELISA
Bortezomib resistant cells were cultured without bortezomib for
at least 3 days, then harvested and lysed in lysis buffer as described
above. A proteasome active site ELISA was used to determine the
levels of constitutive and immunoproteasome active sites and was
performed as described previously [16]. Briefly, protein normal-
ized samples (lysed cells) were incubated with a biotinylated active
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Streptavidin-sepharose beads (GE Healthcare, Sweden) (2.5–5 mL
packed beads per well) were added to 96-well filter plates
(Multiscreen DV; Millipore, Billerica, MA) followed by 70 mLo f
8 M guanidine (Sigma Aldrich) per well to serve as a denaturant
for the samples. Samples were added to the beads and guanidine
for 1 hr at room temperature on a plate shaker. The beads were
washed 5 times with 200 ml/well of ELISA buffer (PBS, 1% bovine
serum albumin, 0.1% tween-20) by vacuum filtration. The beads
were incubated overnight at 4uC on a plate shaker with the
following antibodies recognizing the 6 catalytic subunits diluted
into ELISA buffer: b5 diluted 1:5000; b1, LMP7 and LMP2
diluted 1:2000; b2 diluted 1:3000; and MECL1 diluted 1:1000.
The beads were washed 5 times with 200 ml/well of ELISA buffer
and incubated with HRP-conjugated secondary antibody: goat
anti-rabbit for b5 diluted 1:2000, rabbit anti-goat for MECL1
diluted 1:5000, and goat anti-mouse for LMP7 and LMP2 diluted
1:5000, and goat anti-mouse for b1 and b2 diluted 1:2000 in
ELISA buffer and incubated for 2 hrs at room temperature on a
plate shaker. The beads were washed 5 times with 200 ml/well
ELISA buffer and developed for chemiluminescence signal using
the supersignal ELISA pico substrate (Pierce) following manufac-
turer’s instructions. Luminescence was measured on a plate reader
(Tecan) and converted to ng of proteasome or mg/ml of lysate by
comparison with the 20S proteasome or untreated cell lysate
standard curves. Curve fits were generated using a sigmoidal dose
response equation (Y=Bottom + [(Top-Bottom)/(1+10‘(Lo-
gEC50-X)*HillSlope)where X is the logarithm of concentration
and Y is the response. For proteasome inhibitor studies, active site
probe binding values were expressed as the percent of binding
relative to DMSO-treated cells.
Sequencing of the catalytic subunits
b5, b1, LMP7, LMP2 and b7 subunits were sequenced through
MCLAB (South San Francisco, CA). The open reading frame of
each subunit was amplified from the cDNA and subcloned into a
sequencing vector for analysis.
In silico modeling
All modeling was performed using the Molecular Operating
Environment (MOE) software with default energy minimization
parameters. The Cys63Phe mutation was modeled into the
crystal structure of the a5/b5/b6 yeast proteasome subunits
bound to epoxomicin (PDB# 1G65) or bortezomib (PDB# 2F16)
and into the apo-form structure (PDB# 1RYP). For each model,
Cys63Phe and all sidechains within 4.5 A ˚,w e r ee n e r g y
minimized, followed by an energy minimization of the helix
containing Cys63Phe and all residues within 4.5 A ˚.Af i n a le n e r g y
minimization was performed for the inhibitor bound models
including the helix, the inhibitor molecule, and all side chains
within 4.5 A ˚. The mutant structure files have been graphically
represented in Pymol.
aCGH array and GEP analysis
Cells were cultured continuously in bortezomib for ,1 month
and harvested for gene array analysis. One fraction was lysed in
TRIzol (Invitrogen) and RNA was isolated with PureLink micro-
midi columns (Invitrogen) following the manufactures’ recom-
mendations. DNA was isolated from the second fraction with the
Puregene kit (Qiagen; Valencia, CA). RNA quality was assessed
with an Agilent BioAnalyzer and samples with RIN .9.0 were
labeled and hybridized to HG-133Plus-2.0 GeneChips (Affyme-
trix; Santa Clara, CA). Gene expression levels were extracted from
the raw data using GCRMA package in bioconductor (www.
bioconductor.org) and detection estimates were calculated using
MAS5 in Expression Console (Affymetrix). DNA samples were
digested with DNAseI (Ambion; Foster City, CA) and the
fragmented DNA was labeled with CY5-dUTP using the BioPrime
Plus Labeling kit (Invitrogen). Labeled samples were competitively
hybridized to SurePrint G3 Human CGH 1 M microarrays
(Agilent; Santa Rosa, CA). Copy number abnormalities were
identified in Genomic Workbench V5 (Agilent) using the ADM-2
algorithm and regions of variation between wild-type and resistant
populations were identified. These data are MIAME compliant
and the raw data has been deposited into the MIAME complaint
GEO database.
Statistical analysis
For comparisons of treatment groups, unpaired t-test (Mann-
Whitney), paired t-tests, and one-way or two-way ANOVA (where
appropriate) were performed. For ANOVA, Bonferroni post hoc
analysis was used to compare treatment groups. All statistical
analyses were performed using GraphPad Prism Software (version
4.01). Other differences were assessed by Student t tests.
Differences of p,0.05 were considered significant.
Results
Generation of HT-29 clonal isolates conditioned under
bortezomib pressure
To generate bortezomib-resistant cells, HT-29 cells were
cultured in bulk with continuous step-wise increases in bortezomib
concentration. Cells were grown in the presence of 20 nM
bortezomib (1 month), followed by 60 nM (1 month), then
100 nM (1 month) and 200 nM (1 month). Clonal isolates were
then derived by limiting dilution culture in the presence of
100 nM (BR100) or 200 nM (BR200) bortezomib for an
additional 4 months to establish stable resistance. Three clones
were isolated for each conditioning concentration (100 and
200 nM) and all of the clones were similar in their resistance to
bortezomib as determined by viability studies (Figure 1A). When
kept under constant pressure, the resistant clones showed similar
morphologies to the parental line by light microscopy. However,
the resistant cells displayed slower growth rates and were
qualitatively less adherent when compared to the parental cell
lines (data not shown). When cultured without bortezomib for up
to 40 days, the resistant clones displayed similar adherent
properties and doubling times as the parental cells.
Resistance in BR100 and BR200 is stable and specific to
bortezomib
In parental cells, bortezomib induced cell killing with a 50%
inhibitory concentration (IC50) of 0.013 mM. Compared to
parental cells, BR100 and BR200 cells were 26-63-fold more
resistant to the cytotoxic potential of bortezomib following culture
for 3–40 days in the absence of bortezomib (Figure 1 and Table 1).
The BR100 and BR200 lines were 26-34-fold resistant to
bortezomib when assessed for cell viability at 3 (1 passage) or 14
days (4 passages) after culture without bortezomib (Table 1).
Following 20 days of culture in the absence of bortezomib, the
level of resistance to bortezomib increased to 45-fold and by 40
days had increased to 63-fold in the BR200 cell line, while similar
levels of bortezomib resistance were maintained in the BR100
cells.
Additionally, we tested the resistant cell lines for sensitivity to
other proteasome inhibitors. Carfilzomib is a tetrapeptide
epoxyketone that irreversibly inhibits the proteasome CT-L
subunits and has equimolar cytotoxic potential against parental
Molecular Mechanisms of Bortezomib Resistance
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40 day period, carfilzomib demonstrated relatively potent
cytotoxicity in both the BR100 and BR200 cells, with a resistance
factor of ,5 at all time points. These data suggest that inhibition
in these solid tumor cells can be overcome by other classes of
proteasome inhibitors.
Figure 1. Altered proteasome expression in bortezomib-resistant HT-29 cells. (A) Parental (&,%), BR100 (m, D), and BR200 cells (N,#)
were cultured for 3 or 40 days in the absence of drug prior to exposure to varying concentrations (1 nM–1 mM) of bortezomib (closed symbols) or
carfilzomib (open symbols) for 72 hrs. Viability was normalized to DMSO controls and data are presented as mean viability of triplicate cultures (6
S.E.M). Data is from 1 of 3 replicate experiments with similar results. (B) Western blot analysis of constitutive and immunoproteasome active site
subunits in parental (1), BR100 (2), and BR200 (3) cells cultured in the absence of drug for 14 days. b-actin or GAPDH was used as an to verify equal
loading. (C) Constitutive and immunoproteasome subunit levels (ng subunit/mg total protein) in parental, BR100 and BR200 cell lines cultured in the
absence of drug for 14 or 40 days were measured using ProCISE. Data at day 14 are presented as mean 6 S.D. of 3 independent experiments.
***=P,0.001 by one-way ANOVA followed by Bonferroni’s Multiple Comparison Test. Data at day 40 is representative of one experiment.
doi:10.1371/journal.pone.0027996.g001
Table 1. Cell viability of HT-29, BR100 and BR200 cell lines over a 40-day period.
Parental BR100 BR200
Days removed from
BTZ IC50 (mM) IC50 (mM)
Fold
Resistance IC50 (mM) Fold Resistance
BTZ CFZ BTZ CFZ BTZ CFZ BTZ CFZ BTZ CFZ
3 0.013 0.026 0.41 0.07 326 2.86 0.44 0.1 346 3.86
(0.010–0.018) (0.024–0.034) (0.36–0.48) (0.069–0.075) (0.34–0.59) (0.10–0.20)
14 0.011 0.031 0.34 0.09 266 2.96 0.36 0.11 286 3.56
(0.011–0.016) (0.023–0.033) (0.30–0.37) (0.077–0.093) (0.30–0.44) (0.099–0.12)
20 0.015 0.035 0.42 0.09 286 2.66 0.68 0.15 456 4.36
(0.012–0.018) (0.026–0.037) (0.32–0.54) (0.069–0.11) (0.61–0.74) (0.13–0.17)
40 0.013 0.037 0.62 0.17 486 4.66 0.82 0.15 636 4.16
(0.011–0.015) (0.025–0.042) (0.52–0.72) (0.16–0.21) (0.74–0.90) (0.14–0.17)
The mean IC50 values are presented with 95% confidence intervals from 2 independent experiments in parenthesis.
doi:10.1371/journal.pone.0027996.t001
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proteasome levels and activity
To assess any changes in proteasome levels in the resistant cell
lines, cells cultured for 14 days without bortezomib pressure were
monitored for levels of c20S (b5, b2, b1) and i20S (LMP7, LMP2,
and MECL1) as analyzed by western blotting and quantitatively
confirmed by ProCISE, an active site probe-based proteasome
subunit ELISA (Figure 1B–C). Western blot analysis of the BR100
and BR200 cells showed an increase in levels of all 3 subunits of
the c20S. Changes in immunoproteasome subunit expression were
more varied. LMP7, which was expressed at a low level in the
parental cells, showed a dramatic increase in both resistant cell
lines. Similarly, MECL1, which was undetectable in the parental
cells, was increased in the both the BR100 and BR200 lines.
Conversely, LMP2, which was detectable in the parental lines, did
not show altered expression in the resistant cells.
To enumerate the changes in proteasome levels, we utilized
ProCISE to quantitate active site subunit levels in the 3 cells lines
after 14 days of culture in the absence of drug (Figure 1C). When
compared to parental cells, there was a 3-4-fold increase in all 3
c20S active site subunits. LMP7, which was expressed at 10–30% of
the levels of b5 in parental cells, showed an 8-fold increase in
expression in both resistant cell lines. Similarly, MECL1, demon-
strated a 3-4-fold increase in resistant cells. In contrast, LMP2,
showed no increase in expression level in the resistant cells.
Culturing resistant cells for 40 days in the absence of bortezomib
resulted in normalization of b2 and MECL1 levels and a reduction
in the expression of b5 and LMP7, though the levels of these
subunits remained elevated as compared to parental cells.
Interestingly, levels of b1 remained constant during the culture
period. When the resistant cells were subsequently re-cultured
under continuous bortezomib exposure, the relative levels of
subunits increased in the resistant cells (data not shown). To
determine if the increased levels of proteasome active site subunits
altered catalytic activity, we utilized substrate based assays to
measurechymotrypsin-like(LLVY-AMC),caspase-like(LLE-AMC)
and trypsin-like (VGR-AMC) activities in cells cultured for 3 days in
theabsenceofdrug.Allthreeproteolyticactivitieswereincreased by
3-4-fold in the resistant cells as compared to the parental cells
(Table 2). Taken together, stable resistance to bortezomib results in
increased levels of both constitutive and immunoproteasome active
sites that are further increased by continuous drug exposure.
Genetic characterization of HT-29, BR100 and BR200 cells
To profile gene copy number and expression changes resulting
from bortezomib resistance, array CGH (aCGH) and gene
expression analysis (GEP) were performed on all 3 cell lines.
When compared to parental HT-29 cells, we identified 59 genes
with amplifications and 60 genes with deletions in BR100 and
BR200 cells (Figure S1 and Tables S3, S4, S5, S6, S7). Copy
number alterations were noted in genes that belong to the
transcription and translation, transporters, cell signaling, differen-
tiation and proliferation families of proteins. By expression
analysis, 3134 genes displayed a 2-fold or greater change in gene
expression in both BR100 and BR200 cells (Table S1), including
multiple genes that have been previously reported to be linked
with proteasome inhibition and/or bortezomib resistance (Table
S2).
No deletions or amplifications were identified for genes
encoding proteins found in the 26S proteasome. However,
changes in gene expression levels, which were consistent with
increased subunit levels described above were noted. b5 and b2
expression levels were higher in the resistant cells, but mRNA
levels of b1 and the active sites of the immunoproteasome subunits
did not show a greater than a 2-fold increase. We also detected
increases in structural subunits of the proteasome, including b4,b6,
a2, and a3, and regulatory subunits C1, C3IP, C5, C6, D1, D11,
and D12.
In addition, we sequenced 4 active site subunit genes, b5, b1,
LMP7 and LMP2, and one structural subunit (b7) from multiple
clones in each of the 2 resistant cells lines and compared them to
the sequence of the subunits in the parental cells. We chose these
active sites due to the reported activity of bortezomib against these
proteasome activities [22]. b7 was analyzed since it is the critical
structural subunit required for assembly of a complete 20S
proteasome particle [2]. All resistant clones had a mutation in the
propeptide region (Arg24Cys) and a mutation (Cys63Phe) within
the active site region of b5. In addition, 2 out of the 3 BR200
clones had a Phe50Ile mutation in the propeptide regions of
LMP7. No mutations were found in b1, b7, or LMP2. Taken
together, these data demonstrate that resistance to bortezomib is
correlated with genomic alterations that affect gene expression
levels and that specific point mutations are selected in the b5 gene.
Bortezomib-treated and resistant cells have more rapid
recovery of proteasome activity
In order to determine if the gene expression changes or point
mutations in proteasome active sites resulted in altered proteasome
activity, we measured the inhibitory activity of bortezomib and
carfilzomib against the proteasome CT-L activity in parental and
resistant cells. Both compounds resulted in equivalent levels of
proteasome inhibition 1 hr after exposure in both the BR100 and
BR200 cell line (Figure 2A; Figure S2A).
Next, we exposed the cells to 100 nM of either compound, a
concentration resulting in near complete inhibition of CT-L
activity, for 1 hr prior to washing and culturing in drug free media
for 24 hr. A subset of cells were cultured in the presence of
cycloheximide to block protein translation. CT-L activity was
measured at various time points for recovery of proteasome
activity during the 24 hr culture period. We noted that protea-
some activity in the resistant cells exposed to bortezomib
recovered more quickly in the first 8 hr as compared to the
parental cells (Figure 2B and C; Figure S2B and C). This recovery
was not due to new proteasome production since similar effects
were seen in the presence of cycloheximide. Carfilzomib showed
less recovery of proteasome inhibition as compared to bortezomib
over the 24 hr culture period in parental and resistant cells. The
recovery of CT-L activity following brief exposure to carfilzomib
was similar in resistant and parental cells. When cells were exposed
to carfilzomib and allowed to recover in the presence of
Table 2. Proteasome catalytic activity of HT-29, BR100 and
BR200 cells.
Substrate LLVY VGR LLE
Subunit b5 and LMP7 b2 and MECL1 b1 and LMP2
Activity
Fold
Change Activity
Fold
Change Activity
Fold
Change
Parental 16.568.25 - 27.563.12 - 28.464.24 -
BR100 54.765.32 3.36 97.066.56 3.56 114610.7 4.06
BR200 57.866.33 3.56 92.568.10 3.36 12365.69 4.36
Values presented are mean specific activity (mM AMC released/mg protein) 6
S.D. from 2 independent experiments.
doi:10.1371/journal.pone.0027996.t002
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noted after 1 hr of culture. However, no further recovery of
proteasome activity was noted in carfilzomib treated cells.
We tested 2 other proteasome inhibitors in our resistant cell
lines to further explore the mechanism of proteasome inhibition in
the setting of bortezomib resistance. Leu-Leu-Leu-Aldehyde
(MG132), a peptide aldehyde and completely reversible inhibitor
displayed 8–13 fold resistance with 3 days out of constant
bortezomib pressure (Figure S3). In contrast, no differences in
the potency of proteasome inhibition, kinetics of recovery of
proteasome activity, or cytotoxic potential of Leu-Leu-Leu-
Boronate (LLL-Bor) were noted in a batch cell culture of HT-29
cells resistant to 100 nM bortezomib (Figure S4). In addition, we
determined that this inhibitor, like carfilzomib, is an irreversible
proteasome inhibitor, as determined by monitoring proteasome
recovery in the presence of cycloheximide.
Since sensitivity to LLL-Bor was maintained, de-boronating
enzymes are unlikely to be responsible for the observed resistance
and rapid proteasome activity recovery with bortezomib. Indeed,
no de-boronating enzymes such as cytochrome P450s were found
to be upregulated in the gene expression data (Tables S1, S2, S3,
S4, S5, S6, S7).
Finally, to eliminate the possibility of bortezomib off-target
activity on serine proteases contributing to the resistance
mechanism, we evaluated their expression in the resistant cell
lines. Although cathepsin G, cathepsin A, DPP2 and HtrA2
(chymase was undetectable by western blotting) were found to be
upregulated compared to parental cells after 3 days of culture
without bortezomib pressure, by 14 days of drug free growth,
protein expression levels of these serine off-targets reached similar
levels as compared to parentals (Figure S5). While the immediate
upregulation of the off-target serine proteases may be expected
due to bortezomib exposure, the re-establishment of baseline levels
over time demonstrates that these off-targets are not involved in
the mechanism of resistance in the BR100 and BR200 cells that
remain stably resistant to 40 days.
Cys63Phe mutation in the b5 subunit is critical for
bortezomib binding stability
The altered rates of recovery of CT-L activity in bortezomib
resistant cells and the presence of a mutation in the active site
region of b5 suggested a conformational change in the binding site
structure of this subunit. In order to understand the impact of the
Cys63Phe mutation, we modeled the mutation in the crystal
structures of the yeast proteasome a5/b5/b6 subunits unbound
(apo) or bound to one of 2 inhibitors, bortezomib and epoxomicin,
an epoxyketone related to carfilzomib [21]. Since human b5
shares ,84% homology with the yeast gene, we used the yeast
subunit to model the mutations rather than building a homology
model of the human b5 based on the yeast structure in order to
conserve the integrity of the crystal structure as much as possible.
Cys63 is housed in the same helix as Ala49/50, residues critical for
bortezomib binding [23] (Figure 3A). Based on our model, the
Cys63Phe mutation leads to a shift in the angle of the helix with
respect to the active site (Data not shown). This shift is much more
significant in the inhibitor bound forms than in the unbound form.
This shift did not alter the orientation of epoxomicin but resulted
in a twist in the orientation of bortezomib (Figure 3C). As a result,
Figure 2. Increased proteasome turnover in bortezomib-resistant cells. (A) Parental (&,%) and BR200 cells (N,#) were cultured for 3 days
in the absence of drug prior to exposure to varying concentrations (1 nM–1 mM) of bortezomib (closed symbols) or carfilzomib (open symbols) for
1 hr. Proteasome chymotrypsin-like activity was measured using LLVY-AMC as substrate and specific activity values were normalized to DMSO
controls. Data are presented as the mean relative activity (6 S.E.M.) and is representative of 2 replicate experiments. (B) Parental (&,%) and BR200
cells (N,#) were exposed to 100 nM bortezomib (closed symbols) or carfilzomib (open symbols) for 1 hr, washed and cultured in drug free media with
or without cycloheximide for 1, 2, 4, 6, 8, 12 , and 24 hr prior to measurement of chymotrypsin-like activity. Parental cells (D) and BR200 (e) cells
treated with CHX alone in the absence of drug are included as additional controls. Data are presented as the mean relative activity (6 S.E.M.) and is
representative of 2 replicate experiments. (C) Relative chymotrypsin-like activity in parental and BR200 cells at 4 or 8 hr after a 1 hr pulse exposure to
100 nM bortezomib or carfilzomib in the presence or absence of cycloheximide. **=P,0.01; ***=P,0.001 by one-way ANOVA followed by
Newman-Keuls post-hoc comparisons.
doi:10.1371/journal.pone.0027996.g002
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(Figure 3C). Furthermore, bortezomib binding in the Cys63Phe
mutant resulted in a larger shift of the helix than noted with
epoxomicin (Figure 3B). Taken together, our modeling results
indicate that the Cys63Phe mutation affects the position of the
helix and, therefore, likely affects the binding of bortezomib to b5.
Discussion
The introduction of bortezomib to the armamentarium of
myeloma therapy has resulted significant clinical success but
primary refractoriness and treatment-emergent drug resistance has
deprived a subset of patients of effective therapy [7,8]. To date, in
vitro models of bortezomib resistance have resulted in mutations in
the primary target of bortezomib (b5) that have not yet been
described in bortezomib treated patients [12–14]. In order to
better understand the mechanism of drug resistance, we developed
multiple lines of solid tumor HT-29 cells adapted to continuous
bortezomib pressure. These cells displayed approximately a 30-
fold resistance when compared to parental cells and resistance
increased to 60-fold after long-term culture without bortezomib.
By using ProCISE, a proteasome subunit ELISA, aCGH and GEP
analysis, and comparing the activity of bortezomib to another class
of proteasome inhibitor, we have been able to elucidate some
general themes involved in proteasome resistance. These mech-
anisms of resistance were generally similar to what has been
previously reported with bortezomib adapted hematologic-derived
tumor cell lines (increase in proteasome activity, mutations in the
b5 subunit and genetic alterations in stress response and cell
survival pathways), demonstrating that resistance to this dipeptide
boronate proteasome inhibitor is independent of tumor cell
lineage.
In this study we report novel specific alterations of the
proteasome subunits in resistant cells, previously undescribed
mutations in b5, including one known to occur in MM patients,
and how bortezomib resistance can be overcome with irreversible
proteasome inhibitors. In hematologic-derived tumor cell lines
conditioned to be bortezomib resistant, western blot analysis
demonstrated increased expression of constitutive proteasome
subunits [11,15,17,18]. In both the BR100 and BR200, we noted a
3–4 fold increase in the levels of all c20S and i20S subunits, except
for LMP2. It is noteworthy that bortezomib has been shown in
separate studies to potently target LMP2, including in patient
derived cells [10,24]. With a longer duration of culture following
withdrawal of bortezomib, subunit expression, with the exception
of b1, decreased in the resistant cells but remained elevated
relative to parental cells. Since resistance to bortezomib increased
during this period, these data suggest that increased expression of
proteasome subunits provides only a partial explanation for drug
resistance. Increased subunit levels by ProCISE correlated with
increased mRNA levels as determined by microarray analysis and
a 3-4-fold increase in basal activities of the three catalytic sites as
has been observed before [11,15,17,18]. The consistent elevation
of b1 levels after 40 days, may reflect the 10-fold prolonged half-
life of this protein relative to other active site subunits of the
constitutive proteasome [25]. An increase in b1 levels may also
explain why LMP2 levels did not increase in concordance with
LMP7 and MECL1, as b1 is capable of forming hybrid
proteasomes with immunoproteasome subunits [26]. It is note-
worthy that lower levels of LMP2 expression correlated with
resistance to proteasome inhibition in B-cell tumor lines [27].
Since bortezomib resistance increased during a period in which
proteasome subunit levels decreased, we sought to determine if
altered kinetics of proteasome turnover was also involved in drug
resistance. Indeed, after a 1 hr pulse of bortezomib, proteasome
activity recovered more rapidly in the resistant cells, in particular
during the first 8 hr post drug exposure. This was not a result of
more rapid production of new proteasomes since we also noted
more rapid recovery of proteasome activity following pulse
exposure of bortezomib in the presence of cycloheximide.
Previous studies with hematologic-derived bortezomib resistant
cell lines have shown mutations at 2 key residues in the bortezomib
binding site, Ala49 and 50 [11–13,17]. These adjacent residues are
critical for coordinating a water molecule which is required for
bortezomib stabilization. However, to date, these mutations have
not been identified in the b5 gene in bortezomib refractory
Figure 3. Cys63Phe mutation is a critical structural mutation. (A) Cys63Phe mutation is part of a critical helix at the a5 (cyan)/b5 (gray)
subunit interface subunit that directly points into the active site, with Ala49/50 making direct contacts with proteasome inhibitors. (B) Mutant PRE
unbound (purple) overlaid with mutant PRE bound to bortezomib (olive) and epoxomicin (midnight blue). (C) Active site view of bortezomib and
epoxomicin bound to the wild-type (blue) and mutant (red) PRE2 structures.
doi:10.1371/journal.pone.0027996.g003
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mutation in b5 (Cys63Phe) that resides in the same alpha helix as
Ala49/50, though not directly in the active site. Additionally, our
structural model suggests a conformational and unfavorable shift
of bortezomib within the active site. Although the contribution of
Cys63Phe mutation on bortezomib binding through movement of
the helix would be a long range effect, such allosteric long range
effects have been previously reported between the different active
site b subunits, indicating that the proteasome has a highly
dynamic structure [28]. The fact that proteasome activity recovers
faster in the BTZ resistance cell lines in the presence of
cycloheximide suggest that Cys63Phe increases the dissociation
constant of BTZ, presumably by altering the position of the alpha
helix.
A second mutation found in the resistant cells (Arg24Cys) is
contained within the propeptide portion of the b5 subunit. Like all
proteasome active site subunits, b5 is translated as a proezyme
containing a 49-amino acid propeptide portion that is cleaved
prior to assembly into the b-ring of the proteasome. Previous work
has shown that the portion containing Arg24 is required for proper
subunit processing [2]. Expression of b5 without the propeptide is
lethal in yeast but growth can be restored by expressing the
propeptide as a separate transcript [29,29,29,30]. Therefore, it is
possible that the altered recovery of proteasome activity following
bortezomib exposure is a result of altered b5 processing. It is
noteworthy that the prevalance of Arg24Cys is 5 times higher in
patients with MM than in the general population [31]. Although,
expression of a b5 construct containing Cys at position 24 did not
alter proteasome activity or sensitivity to the proteasome inhibitor
MG262, kinetics of proteasome recovery were not assessed in that
study. Of further note was the presence of a mutation in the
propeptide portion of LMP7 (Phe50Ile) in 2 of 3 BR200 clonal
isolates. Our data suggest that sequencing efforts of proteasome
active sites in bortezomib refractory patient tumor cells may shed
light on the mechanism of clinical resistance.
By both aCGH and GEP analysis, the genetic profiles of BR100
and BR200 were found to be similar. In corroboration with
protein analysis, we found upregulation of several proteasome
genes (catalytic, structural, and regulatory subunits) in resistant
cells. However, deletion or reduced expression of several gene
families was surprising since their elevated levels have been linked
to bortezomib resistance. We found that co-factors of HSP70 were
deleted and together with amplification of a chromosomal region
containing a negative regulator of HSP70 suggests that HSP70
activity is being suppressed in resistant cells. Given that HSP70
activation is associated with bortezomib resistance in lymphoma
cells [32], our results suggest that alterations in this pathway are
not causal mediators of resistance. Increased expression of another
heat shock protein, HSP27, was noted in BR100 and BR200 cells.
Increased expression of HSP27 has been determined to be
associated with BTZ in lymphoma cells in vitro and in patients
refractory to bortezomib [32,33]. Since increase levels of HSP27
were also associated with poor prognosis in dexamethasone-
treated patients, this may represent a general mechanism of drug
resistance.
Importantly, we determined that resistance to bortezomib could
be overcome by two other proteasome inhibitors. Carfilzomib,
which has demonstrated activity in bortezomib relapsed and
refractory MM patients [34], showed only a 3–4 fold decrease in
cytotoxic potential in the BR100 and BR200 cells. This modest
change in cytotoxicity was equivalent to the increase in
proteasome enzymatic activity noted in the same cells. Since
carfilzomib remained sensitive in both MM and DLBCL lines
made ,5 fold resistant to bortezomib, we hypothesize that
carfilzomib can overcome bortezomib resistance across multiple
histotypes and varying degrees of resistance [35,36]. Another
irreversible proteasome inhibitor, LLL-Bor, was also equivalently
cytotoxic to both resistant and parental cells, while the cells
remained refractory to a reversible inhibitor MG132. Further,
bortezomib off-target activity does not likely play a role in the
resistance mechanism since there was no stable increase in
expression of these proteases. The results with these compounds
suggest that bortezomib resistance, and the subsequent genetic and
protein expression changes, do not result in resistance to all classes
of proteasome inhibitors. These data also suggest that expression
of markers of multidrug resistance, such as HSP27, does not
predict for resistance to carfilzomib treatment.
Carfilzomib differs from bortezomib in the mechanism of
proteasome inhibition mediated by the pharmacophore. Similar to
epoxomicin, carfilzomib contains an epoxyketone moiety which
forms a dual covalent morpholino adduct with the N-terminal
threonine of the proteasome active sites [37]. Consistent with this,
we noted that there was no recovery of proteasome activity in
tumor cells following a pulse treatment of carfilzomib in the
presence of cycloheximide. This irreversible mechanism of
inhibition results in a longer duration of proteasome inhibition
as compared to bortezomib. Furthermore, in bortezomib-resistant
cells, recovery of proteasome activity following a pulse treatment
with carfilzomib was equivalent to that seen in parental cells.
Similar findings were also seen with LLL-Bor, which we also
determined to be an irreversible inhibitor. This suggests that
inhibition of b5 by irreversible inhibitors such as carfilzomib is
unaffected by the mutational status. Indeed, structural modeling
suggests that epoxomicin binding to the b5 active site was
unaffected by the mutation at position 63. Previously, we had
shown that in a panel of tumor cells, carfilzomib had greater
cytotoxic potential than bortezomib when both agents were
exposed to tumor cells for 1 hr prior to a 72 hr culture [21].
Together with the data we report here, this suggests that the
prolonged duration of proteasome inhibition achieved with
carfilzomib results in a greater anti-tumor response. In conclusion,
these data present the description of cell lines and assays to show
the biochemical and genetic study of bortezomib resistance in vitro
and that resistance to one class of proteasome inhibitor can be
overcome by the introduction of potent, irreversible inhibitors.
Supporting Information
Figure S1 Whole Genome Comparison of HT-29 Vari-
ants. Regions of DNA content gain and loss are shown for
chromosomes 1–22, X and Y.
(TIF)
Figure S2 Increased proteasome turnover in bortezo-
mib resistant cells. (A) Parental (&,%) and BR100 cells (N,#)
were cultured for 3 days in the absence of drug prior to exposure
to varying concentrations (1 nM–1 mM) bortezomib (closed
symbols) or carfilzomib (open symbols) for 1 hr. Proteasome
chymotrypsin-like activity was measured using LLVY-AMC as
substrate and specific activity values were normalized to DMSO
controls. Data are presented as the mean relative activity (6
S.E.M.) and is from 1 of 2 replicate experiments. (B) Parental
(&,%) and BR100 cells (N,#) were exposed to 100 nM bortezomib
(closed symbols) or carfilzomib (open symbols) for 1 hr, washed
and cultured in drug free media with or without cycloheximide for
1, 2, 4, 6, 8, 12 , and 24 hr prior to measurement of chymotrypsin
like activity. As additional controls, parental (open triangle) cells
treated with CHX alone in the absence of drug are compared to
cells treated with DMSO. BR100 (e) cells treated with CHX
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e27996alone in the absence of drug are compared to parental cells treated
with DMSO. Data are presented as the mean relative activity (6
S.E.M.) and is from 1 of 2 replicate experiments. (C) Relative
chymotrypsin-like activity in parental and BR100 cells 4 or 8 hr
after a 1 hr pulse exposure to 100 nM bortezomib or carfilzomib
in the presence or absence of cycloheximide. **=P,0.01;
***=P,0.001 by one-way ANOVA followed by Newman-Keuls
post-hoc comparisons.
(TIF)
Figure S3 Effect of MG132 in parental and HT-29
resistant cells. (A) Parental cells were cultured for 3 days with
bortezomib exposure, allowed to recover for 3 days, then treated
for 72 hrs with a dose range of MG132, bortezomib and
carfilzomib and cell viability was assessed using CellTiter glo.
Open triangles denote effect of MG132, black circles denote effect
of carfilzomib and black squares represent bortezomib. (B) BR100
cells were cultured for 3 days and treated with either MG132,
carfilzomib or bortezomib as described in (A). (C) BR200 cells
were cultured and treated with drug as described in (A). (D) IC50
values for the curves in (A–C) is shown above. Data are presented
as the mean relative activity (6 S.E.M.) and is from 1 of 2 replicate
experiments.
(TIF)
Figure S4 Characterization of LLL-boronate in BR100
batch cells. (A) Parental cells were cultured for 3–40 days with
bortezomib exposure, allowed to recover for 3 days, then treated
for 72 hrs with a dose range of bortezomib and LLL-boronate and
cell viability was assessed using CellTiter glo. Square shapes
denote bortezomib data and triangles denote response with LLL-
boronate. The same compounds were used in a batch population
of cells resistant to 100 nM bortezomib (right panel). (B) Percent
chymotrypsin-like activity at the 4 hr time point for the 100 nM
bortezomib dose and LLL-boronate in parental cells (left panel)
and in batch cells resistant to 100 nM bortezomib (right panel). (C)
Parental (&,%) and BR100 batch cells (N,#) were exposed to
100 nM bortezomib (closed symbols) or LLL-boronate (open
symbols) for 1 hr, washed and cultured in drug free media with or
without cycloheximide for 1, 2, 4, 6, 8, 12 , and 24 hr prior to
measurement of chymotrypsin like activity. Data are presented as
the mean relative activity (6 S.E.M.) and is from 1 of 2 replicate
experiments.
(TIF)
Figure S5 Serine Protease off-target activity in bortezo-
mib-resistant cells. BR100 and BR200 cells were cultured
without bortezomib for 3 or 14 days, along with parental cells, and
cells were harvested for immunoblot analysis. Either cell lysates
from PBMCs or SH-SY5Y cells were used as appropriate controls.
Data are representative of 2 separate experiments.
(TIF)
Table S1 Genes with Two Fold or Greater Change in
Gene Expression in both BR100 and BR200.
(XLSX)
Table S2 Fold Change of Genes Expressed in Wild-type
and/or Resistant Cell Lines Related to Proteasome
Function or Drug Resistance.
(XLSX)
Table S3 Genes Deleted in BR100 with a Two Fold or
Greater Gene Expression Change.
(XLSX)
Table S4 Genes Deleted in BR200 with a Two Fold or
Greater Gene Expression Change.
(XLSX)
Table S5 Genes Amplified in BR100 with a Two Fold or
Greater Gene Expression Change.
(XLSX)
Table S6 Genes Amplified in BR200 with a Two Fold or
Greater Gene Expression Change.
(XLSX)
Table S7 Summary of Tables S3, S4, S5, S6.
(XLSX)
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